Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd ADR (NY: RDY )

14.27 +0.28 (+2.00%)
Streaming Delayed Price Updated: 10:04 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd ADR

< Previous 1 2 3 4 5 6 Next >
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 
Via News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
By Kenneth Adams, Benzinga 
Via TheNewswire.com
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. 
Via Benzinga
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Intercept Settles Ocaliva Litigation With Reddy's Lab
Via Benzinga
India Based Pharma Companies In Race To Buy Athenex, Shares Surge
Via Benzinga
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal
Via Benzinga
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Eton Pharma Shares Tick Higher After Offloading Hospital Products
Via Benzinga
The 3 Most Undervalued Stocks in India for Your February Buy List
These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years. 
Via InvestorPlace
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Intercept entered a deal with Amneal, likely lining up a series of new settlements. 
Via Investor's Business Daily
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Journey Medical Touts Positive PK Data For Bacterial Infection Candidate
Via Benzinga
Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
From Dr. Reddy’s Laboratories Ltd. 500124
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
From Aurigene Discovery Technologies Limited
Via Business Wire
Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.